Monoclonal antibody therapies and neurologic disorders.
The role of monoclonal antibody (mAb) therapies in treating medical conditions has expanded tremendously since its inception in the 1970s, and their use in neurologic conditions has increased in just the past few years. Currently, mAb treatments are being tested in conditions ranging from neuromuscular disorders to demyelinating diseases. What is now considered experimental therapy may soon become common. In addition, neurologic adverse effects have been reported during the use of mAb therapy in nonneurologic conditions that neurologists should be able to recognize. Because of the rapid increase in the use of mAb treatments, this review highlights their use in neurologic conditions and their neurologic adverse effects.
Novak
John C
JC
Department of Neurology, The Ohio State University Medical Center, 1654 Upham Dr, Columbus, OH 43210, USA. Michael.Racke@osumc.edu
Lovett-Racke
Amy E
AE
Racke
Michael K
MK
D000818:Animals; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000502:physiology / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods; D009422:Nervous System Diseases / Q000276:immunology / Q000378:metabolism / Q000628:therapy*
D000911:Antibodies, Monoclonal